Logo image of SLNO

SOLENO THERAPEUTICS INC (SLNO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SLNO - US8342033094 - Common Stock

42.48 USD
+0.53 (+1.26%)
Last: 1/16/2026, 8:00:02 PM
43.7 USD
+1.22 (+2.87%)
After Hours: 1/16/2026, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SLNO. SLNO was compared to 528 industry peers in the Biotechnology industry. The financial health of SLNO is average, but there are quite some concerns on its profitability. SLNO has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • SLNO had negative earnings in the past year.
  • SLNO had a negative operating cash flow in the past year.
  • SLNO had negative earnings in each of the past 5 years.
  • In the past 5 years SLNO always reported negative operating cash flow.
SLNO Yearly Net Income VS EBIT VS OCF VS FCFSLNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • With an excellent Return On Assets value of -13.08%, SLNO belongs to the best of the industry, outperforming 82.01% of the companies in the same industry.
  • SLNO has a better Return On Equity (-15.85%) than 85.23% of its industry peers.
Industry RankSector Rank
ROA -13.08%
ROE -15.85%
ROIC N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
SLNO Yearly ROA, ROE, ROICSLNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • SLNO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLNO Yearly Profit, Operating, Gross MarginsSLNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, SLNO has more shares outstanding
  • SLNO has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, SLNO has a worse debt to assets ratio.
SLNO Yearly Shares OutstandingSLNO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLNO Yearly Total Debt VS Total AssetsSLNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 12.43 indicates that SLNO is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 12.43, SLNO belongs to the top of the industry, outperforming 84.47% of the companies in the same industry.
  • A Debt/Equity ratio of 0.10 indicates that SLNO is not too dependend on debt financing.
  • SLNO has a worse Debt to Equity ratio (0.10) than 62.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z 12.43
ROIC/WACCN/A
WACCN/A
SLNO Yearly LT Debt VS Equity VS FCFSLNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • SLNO has a Current Ratio of 16.08. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 16.08, SLNO belongs to the top of the industry, outperforming 92.99% of the companies in the same industry.
  • A Quick Ratio of 15.88 indicates that SLNO has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 15.88, SLNO belongs to the best of the industry, outperforming 92.99% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.08
Quick Ratio 15.88
SLNO Yearly Current Assets VS Current LiabilitesSLNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 44.58% over the past year.
EPS 1Y (TTM)44.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, SLNO will show a very strong growth in Earnings Per Share. The EPS will grow by 53.58% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.4%
EPS Next 2Y70.29%
EPS Next 3Y53.58%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLNO Yearly Revenue VS EstimatesSLNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2025 2026 2027 200M 400M 600M
SLNO Yearly EPS VS EstimatesSLNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50 -100 -150

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SLNO. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 11.08 indicates a reasonable valuation of SLNO.
  • 98.11% of the companies in the same industry are more expensive than SLNO, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.26, SLNO is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 11.08
SLNO Price Earnings VS Forward Price EarningsSLNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLNO Per share dataSLNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as SLNO's earnings are expected to grow with 53.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y70.29%
EPS Next 3Y53.58%

More info and screens

0

5. Dividend

5.1 Amount

  • SLNO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (1/16/2026, 8:00:02 PM)

After market: 43.7 +1.22 (+2.87%)

42.48

+0.53 (+1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-12
Earnings (Next)05-05
Inst Owners124.99%
Inst Owner Change0.62%
Ins Owners1.26%
Ins Owner Change-2.9%
Market Cap2.28B
Revenue(TTM)98.67M
Net Income(TTM)-78.45M
Analysts86.32
Price Target112.75 (165.42%)
Short Float %17.56%
Short Ratio5.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)419.9%
Min EPS beat(2)80.77%
Max EPS beat(2)759.03%
EPS beat(4)2
Avg EPS beat(4)207.86%
Min EPS beat(4)-7.96%
Max EPS beat(4)759.03%
EPS beat(8)3
Avg EPS beat(8)72.02%
EPS beat(12)5
Avg EPS beat(12)44.04%
EPS beat(16)8
Avg EPS beat(16)37.6%
Revenue beat(2)2
Avg Revenue beat(2)30.96%
Min Revenue beat(2)27.34%
Max Revenue beat(2)34.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.37%
EPS NQ rev (1m)0.55%
EPS NQ rev (3m)175.1%
EPS NY rev (1m)50.82%
EPS NY rev (3m)91.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)32.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)27.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 11.08
P/S 23.12
P/FCF N/A
P/OCF N/A
P/B 4.61
P/tB 4.66
EV/EBITDA N/A
EPS(TTM)-1.84
EYN/A
EPS(NY)3.83
Fwd EY9.02%
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS1.84
BVpS9.21
TBVpS9.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.08%
ROE -15.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.14%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.08
Quick Ratio 15.88
Altman-Z 12.43
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.83%
Cap/Depr(5y)2.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125.68%
EPS Next Y98.4%
EPS Next 2Y70.29%
EPS Next 3Y53.58%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year105.97%
EBIT Next 3Y70.33%
EBIT Next 5YN/A
FCF growth 1Y-9.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.95%
OCF growth 3YN/A
OCF growth 5YN/A

SOLENO THERAPEUTICS INC / SLNO FAQ

What is the ChartMill fundamental rating of SOLENO THERAPEUTICS INC (SLNO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SLNO.


Can you provide the valuation status for SOLENO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to SOLENO THERAPEUTICS INC (SLNO). This can be considered as Fairly Valued.


How profitable is SOLENO THERAPEUTICS INC (SLNO) stock?

SOLENO THERAPEUTICS INC (SLNO) has a profitability rating of 2 / 10.


Can you provide the financial health for SLNO stock?

The financial health rating of SOLENO THERAPEUTICS INC (SLNO) is 5 / 10.